

Date and Time: Tuesday 14th & Wednesday 15th January 2014

Minutes: confirmed

GDG Meeting 10: Dyspepsia & GORD

Place: Lowry House, Red Rooms

**Present:** Peter Barry (Chair) (PB)

Hugh Barr (HB)

John de Caestecker (JD)

Mark Follows (MF)
Ann Harding (AH)
Janusz Jankowski (JJ)
Mimi McCord (MM)
Alex Ford (AF)

**Apologies:** 

In attendance:

NICE Staff:

Emma Banks (EB)
Ben Doak (BD)
Ruth Garnett (RG)
Michael Heath (MH)

Rachel Houten (RH)

Sarah Palombella (SP) Gabriel Rogers (GR)

Toni Tan (TT)

Jonathan Underhill (JU)

Chris Gibbons (CG) 14/01 am

### **Notes**

## Tuesday 14th January 2014

- 1. PB welcomed the group to the 10<sup>th</sup> meeting of this GDG. Minutes for the previous meeting were agreed without amendment.
- 2. All GDG members were asked to share any new conflicts of interest which have not been previously declared. No new conflicted were declared but it was agreed that due to JJs level of involvement with AspECT trial he would not be participate in the drafting of recommendations for review question 4. No new conflicts were declared by the NICE team.
- 3. RR gave a presentation relating to review question (RQ) 4: "What is the clinical effectiveness of PPIs in patients with severe erosive reflux disease?". The GDG reviewed and discussed the evidence, agreed the evidence statements and agreed recommendations for the question.

#### **Notes**

# Tuesday 14<sup>th</sup> January 2014

- 4. TT gave a presentation relating to RQ 7: "What other management is effective for patients who do not respond to PPIs, H2 receptor antagonists, or H pylori eradication despite optimum primary care, or patients who have relapsed following surgery?". The GDG reviewed and discussed the evidence, agreed the evidence statements and agreed recommendations for the question.
- 5. GR gave the group a progress report on the update searches relating to the H. pylori review question.
- 6. PB closed the meeting.

### Wednesday 15<sup>th</sup> January 2014

- 1. PB welcomed the group to day 2 of the meeting.
- 2. TT gave the group a progress report on the update searches relating to the remaining review questions.
- 3. BD gave the group an update on the Referral for suspected cancer clinical guideline.
- 4. EB took the group through a review of the guideline, including the format, content and recommendations.
- 5. PB closed the meeting and thanked the group for attending and all their hard work during the development of this guideline.